The aim of the Centre is to contribute to the improvement of outcomes for eye-care. This will be achieved by expanding the evidence base for clinical interventions, particularly patient-centred outcomes, informing professionals who deliver eye-care of the evidence base and increasing access to care. The Centre will increase the evidence base by expanding the Australian Corneal Graft Registry, establishing other national registries, and by conducting clinical trials. It will increase access to ca ....The aim of the Centre is to contribute to the improvement of outcomes for eye-care. This will be achieved by expanding the evidence base for clinical interventions, particularly patient-centred outcomes, informing professionals who deliver eye-care of the evidence base and increasing access to care. The Centre will increase the evidence base by expanding the Australian Corneal Graft Registry, establishing other national registries, and by conducting clinical trials. It will increase access to care by establishing new models of eye care delivery for common eye problems in urban and remote populations and by developing efficient and cost-effective pathways to care which utilise a wide range of eye-care professionals.Read moreRead less
Heart rhythm devices have revolutionised the survival of patients with heart disease. However we still do not know precisely what the outcomes are in patients attending our local hospitals. We will develop a registry for these devices to monitor and benchmark their performance throughout the state. The development of a registry enables us to assess the quality of health services at a local level. This project has the potential to improve the health outcomes of 4 million people with heart disease
Genetic and environmental causes of asthma are poorly understood. The WATCH for asthma project will study Western Australian (WA) families in which there was a twin or higher order multiple birth (twin families) in order to measure inherited and environmental contributions to the development of asthma. All WA twin families, whose infants were born during 1990 to 1995, will be invited to become part of an existing Healthway funded, population based registry of WA Twin Child Health (the WATCH stud ....Genetic and environmental causes of asthma are poorly understood. The WATCH for asthma project will study Western Australian (WA) families in which there was a twin or higher order multiple birth (twin families) in order to measure inherited and environmental contributions to the development of asthma. All WA twin families, whose infants were born during 1990 to 1995, will be invited to become part of an existing Healthway funded, population based registry of WA Twin Child Health (the WATCH study). The WATCH study has already invited 2,751 WA twin families to participate and is the only population based twin study in Australia. Funding of this study by NH and MRC will enable the extension of this unique registry to include more specific clinical information about those families in which one or more of the twins has asthma. In addition to questionnaire data, DNA and physiological information will be collected, including a potentially important new measure of airway inflammation, exhaled nitric oxide which has yet to be studied for familial aggregation. We will use the extended WATCH dataset to undertake a comprehensive investigation of the genetic epidemiology of childhood asthma. This work offers the potential to advance our current understanding of the causes of both childhood asthma and associated traits (e.g., 'twitchy' airways). By exploring the relationships between different components of asthma, we will generate information to assist us to design better epidemiological and genetic studies of asthma. At the time of recruitment, if consent is given, blood will also be taken for DNA extraction and frozen storage. This will generate a powerful data base that can later be used for to search at a molecular level for genes potentially important in causing childhood asthma. Finally, by extending the WATCH study database we will be enhancing a research resource that could potentially be used for future studies of common complex diseases other than asthma.Read moreRead less
Antibody-mediated Dendritic Cell Depletion To Attenuate GVHD
Funder
National Health and Medical Research Council
Funding Amount
$434,510.00
Summary
Not all patients with leukemia will be cured by chemotherapy. Stem cell transplantation improves their chances of survival. Stem cell transplantation requires intensive chemotherapy and radiotherapy to eradicate the underlying disease and infusion of healthy stem cells to provide an anti-leukemic effect and normal blood cells. Recovery from transplantation is not straightforward. Recovery can be hampered by the immunological reaction of the donor cells against the patient (Graft versus Host Dise ....Not all patients with leukemia will be cured by chemotherapy. Stem cell transplantation improves their chances of survival. Stem cell transplantation requires intensive chemotherapy and radiotherapy to eradicate the underlying disease and infusion of healthy stem cells to provide an anti-leukemic effect and normal blood cells. Recovery from transplantation is not straightforward. Recovery can be hampered by the immunological reaction of the donor cells against the patient (Graft versus Host Disease [GVHD]), despite immunosuppression. GVHD produces serious damage to the internal organs and lining of the mouth and gut. Recovery can also be circumvented by leukemic relapse. GVHD is associated with an increased risk of death and dying after transplantation. To date therapy for GVHD has relied on eliminating the T cells that cause the disease. However for T cells to cause damage they must first be primed with antigen presented on activated dendritic cells. The intensive conditioning therapy required to eradicate the underlying disease before transplantation also activates dendritic cells. Our project seeks to investigate the effects of lethal and non-lethal conditioning on dendritic cells with the aim of validating the use of antibodies designed to deplete activated dendritic cells as therapy for graft versus host disease.Read moreRead less
The transplantation of healthy stem cells from a donor into a recipient with blood cancer (stem cell transplantation) is the most effective curative therapy for the majority of patients. Unfortunately this process results in unwanted, often fatal, side effects including infection, a rejection process known as graft-versus-host disease and in some patients, the leukaemia still recurs. This research will refine new treatments focused on overcoming these limitations and improving transplant outcome
The goal of our work is to improve outcomes for patients who are blind or seriously visually impaired as a result of corneal disease. Such patients can regain vision through a corneal transplant, but many such transplants fail. A corneal graft may fail because of an unwanted immune response, because blood vessels grow into the graft, or because some corneal cells die. We plan to transfer genes to the donor cornea in the laboratory, prior to corneal transplantation, to avoid such failure.
Antibiotic Loading Of Bone Allografts For The Prevention Of Peri-operative Infection
Funder
National Health and Medical Research Council
Funding Amount
$300,847.00
Summary
Bone is the second most often transplanted tissue after blood, with thousands of grafts done every year in Australia. Allograft bone (taken from another person) is used to replace bone removed due to cancer, but is prone to infection. Infected grafts must be removed, and can lead to amputation. We are developing a process to put antibiotics into allograft bone, to prevent infections from taking hold. Reducing infections can increase the success of limb salvage surgery for cancer patients.